Jeremy S. Connors

Hematology | Oncology
1515 Holcombe Blvd
Houston, TX 77030

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications

Resolution of Neuroblastoma-Related Opsoclonus-Myoclonus Ataxia Syndrome Following Tandem High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation and Extensive Intravenous Immunoglobulin.

Resolution of Neuroblastoma-Related Opsoclonus-Myoclonus Ataxia Syndrome Following Tandem High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation and Extensive Intravenous Immunoglobulin.

Journal: Pediatric blood & cancer
Published: July 17, 2026

Pre-transplant immunosuppression in pediatric patients undergoing haploidentical stem cell transplant for sickle cell disease is associated with positive outcomes.

Pre-transplant immunosuppression in pediatric patients undergoing haploidentical stem cell transplant for sickle cell disease is associated with positive outcomes.

Journal: Bone marrow transplantation
Published: August 21, 2025

Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.

Immune-related toxicity profile after haematopoietic stem cell transplantation in patients with B-ALL given combination immunotherapy with rituximab, inotuzumab and blinatumomab.

Journal: British journal of haematology
Published: August 21, 2025

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors.

Gemcitabine, Docetaxel, Melphalan, Carboplatin as Part of Sequential Cycles of High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Rescue for Multiply Relapsed/Refractory Pediatric Germ Cell Tumors.

Journal: Pediatric blood & cancer
Published: July 18, 2025

Allogeneic Hematopoietic Stem Cell Transplant for an Unknown Inherited Bone Marrow Failure Syndrome With a Novel Compound Heterozygous Mutation.

Allogeneic Hematopoietic Stem Cell Transplant for an Unknown Inherited Bone Marrow Failure Syndrome With a Novel Compound Heterozygous Mutation.

Journal: Pediatric blood & cancer
Published: May 06, 2025

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML.

Journal: Blood
Published: April 01, 2025

Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia.

Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia.

Journal: Blood advances
Published: December 03, 2024

Immunotherapy-related neurotoxicity in the central nervous system of children with cancer.

Immunotherapy-related neurotoxicity in the central nervous system of children with cancer.

Journal: Neuro-oncology
Published: November 13, 2024

Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.

Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.

Journal: Leukemia
Published: June 04, 2024

Observation and Management of Juvenile Myelomonocytic Leukemia and Noonan Syndrome-Associated Myeloproliferative Disorder: A Real-World Experience.

Observation and Management of Juvenile Myelomonocytic Leukemia and Noonan Syndrome-Associated Myeloproliferative Disorder: A Real-World Experience.

Journal: Cancers
Published: May 07, 2024

Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia.

Venetoclax for pediatric patients with newly diagnosed acute myeloid leukemia.

Journal: Pediatric blood & cancer
Published: March 07, 2024

Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia.

Palbociclib and chemotherapy followed by blinatumomab consolidation to CAR-T cell therapy in KMT2A-rearranged, therapy-related acute lymphoblastic leukemia.

Journal: Pediatric blood & cancer
Published: February 27, 2024
Showing 1-12 of 17

Last Updated: 09/26/2026